Prenatal exposure to maternal asthma and asthma medication and neurodevelopmental outcomes: a population cohort study of 179,024 children

ObjectivesTo investigate the associations between treated and untreated asthma during pregnancy and neurodevelopmental outcomes in the offspring, including autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD) and learning difficulties, and to determine whether these associations are specific to one or more class of asthma medication. MethodsA population-based retrospective birth cohort was constructed using linked health and education records of children liveborn in Wales between 2009 and 2016, with up to 13 years follow-up, to mothers registered with a Secure Anonymised Information Linkage (SAIL)-contributing general practice for at least two years before delivery. Generalized estimating equations with a binomial distribution and logit link function were employed to evaluate associations between treated and untreated maternal asthma and special education needs (SEN) in the offspring. Survival analyses were used to investigate associations with ADHD. ResultsAmong 179,024 children (49.4% female, mean age 5.68 years (SD 1.11)), 11,991 (6.7%) had mothers with treated asthma, 4,927 (2.8%) mothers with untreated asthma, and 5,265 (2.9%) mothers who took asthma medication without a recorded asthma diagnosis. SEN was recorded in 50,955 (28.5%) children. Prenatal exposure to short-acting beta agonists (SABA) was associated with increased risk of SEN (aOR 1.23, 95% CI 1.18-1.28) and ADHD (aHR 1.39, 95% CI 1.23-1.56), with similar risks for inhaled corticosteroids (ICS). Untreated maternal asthma was also associated with SEN (aOR 1.14, 95% CI 1.07-1.23) and ADHD (aHR 1.70, 95% CI 1.42-2.05), suggesting that asthma itself contributes to risk. In contrast, ASD was associated with SABA with or without other asthma medication (aOR 1.20, 95% CI 1.05-1.37) and not with untreated maternal asthma. ConclusionPrenatal exposure to SABA was associated with a higher risk of ASD. Asthma treatment is required during pregnancy but treatment choices need to carefully balance potential maternal and offspring risks.

Authors

Institutions

Publication Details

Journal
International Journal for Population Data Science
Published
2025-08-28
DOI
https://doi.org/10.23889/ijpds.v10i4.3292
Primary Topic
Pregnancy and Medication Impact
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prenatal exposure to maternal asthma and asthma medication and neurodevelopmental outcomes: a population cohort study of 179,024 children

Scott McGill Nelson, Michael Fleming, Jill P. Pell, Daniel Mackay et al.
1 links
International Journal for Population Data Science
Pregnancy and Medication Impact
article

Prenatal exposure to maternal asthma and asthma medication and neurodevelopmental outcomes: a population cohort study of 179,024 children

Scott McGill Nelson, Michael Fleming, Jill P. Pell, Daniel Mackay, Claire E. Hastie, Sarjit Singh, Lama A Shakhshir, Logesh Sivakumar
article en

Abstract

ObjectivesTo investigate the associations between treated and untreated asthma during pregnancy and neurodevelopmental outcomes in the offspring, including autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD) and learning difficulties, and to determine whether these associations are specific to one or more class of asthma medication. MethodsA population-based retrospective birth cohort was constructed using linked health and education records of children liveborn in Wales between 2009 and 2016, with up to 13 years follow-up, to mothers registered with a Secure Anonymised Information Linkage (SAIL)-contributing general practice for at least two years before delivery. Generalized estimating equations with a binomial distribution and logit link function were employed to evaluate associations between treated and untreated maternal asthma and special education needs (SEN) in the offspring. Survival analyses were used to investigate associations with ADHD. ResultsAmong 179,024 children (49.4% female, mean age 5.68 years (SD 1.11)), 11,991 (6.7%) had mothers with treated asthma, 4,927 (2.8%) mothers with untreated asthma, and 5,265 (2.9%) mothers who took asthma medication without a recorded asthma diagnosis. SEN was recorded in 50,955 (28.5%) children. Prenatal exposure to short-acting beta agonists (SABA) was associated with increased risk of SEN (aOR 1.23, 95% CI 1.18-1.28) and ADHD (aHR 1.39, 95% CI 1.23-1.56), with similar risks for inhaled corticosteroids (ICS). Untreated maternal asthma was also associated with SEN (aOR 1.14, 95% CI 1.07-1.23) and ADHD (aHR 1.70, 95% CI 1.42-2.05), suggesting that asthma itself contributes to risk. In contrast, ASD was associated with SABA with or without other asthma medication (aOR 1.20, 95% CI 1.05-1.37) and not with untreated maternal asthma. ConclusionPrenatal exposure to SABA was associated with a higher risk of ASD. Asthma treatment is required during pregnancy but treatment choices need to carefully balance potential maternal and offspring risks.

International Journal for Population Data ScienceVol. 10(4)
University of Glasgow (GB)
Openalex Percentile: Top 69%
Pregnancy and Medication Impact
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.